Comparison of efficacy and safety between high-dose amoxicillin-vonoprazan dual therapy and bismuth-based quadruple therapy for Helicobacter pylori eradication

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052550

Enrollment

Unknown

Registered

2021-10-30

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

experimental group:high-dose amoxicillin-vonoprazan dual therapy

control group:bismuth-based quadruple therapy

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 70 years; 2. 13C urea breath test was positive; 3. In accordance with the helicobacter pylori eradication indicators (according to the "Fifth National Consensus Report on helicobacter pylori Infection Management"); 4. No previous helicobacter pylori eradication treatment.

Exclusion criteria

Exclusion criteria: 1. Patients allergic to the drugs used in the eradication programme; 2. Patients with a history of ß-lactam drug allergy, allergic constitution and allergic reaction; 3. After gastric surgery; 4. Pregnant and lactating women; 5. Taking glucocorticoids, non-steroidal drugs or anticoagulants; 6. Patients with low body weight (body weight less than 40kg), complicated with severe liver, kidney and heart insufficiency, malignant tumor and cerebrovascular disease.

Design outcomes

Primary

Measure	Time frame
13C urea breath test;	—

Countries

China

Contacts

Public ContactWang Weihong

Peking University First Hospital

wangweihong2581@163.com+86 13041171610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026